|
 |
AtomoxetineThis page contains recent news articles, when available, and an overview of Atomoxetine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Atomoxetine (when available) Atomoxetine is an amphetamine used to treat ADD/ADHD in children and adults. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. It increases motor activity and mental alertness, and reduces drowsiness and a sense of fatigue, decreasing motor restlessness and improves one's ability to focus. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence which clearly establishes the mechanism whereby amphetamine produces mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system. Atomoxetine activates the brain stem arousal system and cortex to produce its stimulant effect. For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Mechanism Of Action: Amphetamines release stores of norepinephrine and dopamine from nerve endings by converting the respective molecular transporters into open channels. Amphetamines also releases stores of serotonin from synaptic vesicles. Like methylphenidate (Ritalin) amphetamines also prevent the monoamine transporters for dopamine and norepinephrine from recycling them (called reuptake inhibition) which leads to increased amounts of dopamine and norepinephrine in synaptic clefts. These combined effects rapidly increases the concentrations of the respective neurotransmitters in the synaptic cleft, which promotes nerve impulse transmission in neurons that have those receptors. News Articles on Atomoxetine Research from University of California provide new insights into life sciences ... - Dec 31, 2009 A report, 'Atomoxetine versus stimulants in the community treatment of children with ADHD: an electronic diary study,' is newly published data in Journal of ... Behavioral Health Central (blog) Atomoxetine for the treatment of attention-deficit/hyperactivity disorder ... - Dec 15, 2009 The objective of this study was to assess the effects of atomoxetine on treating attention-deficit/hyperactivity disorder (ADHD), on reading performance, ... 7thSpace Interactive (press release) Glenmark unit gets tentative FDA nod for 2 drugs - Dec 24, 2009 The second drug, Atomoxetine Hydrochloride, is used in the treatment of attention deficit or hyperactivity disorder, and has an estimated market size of ... Moneycontrol.com FDA Grants Tentative Approval To GGI For Pramipexole Dihydrochloride Tablets - Dec 28, 2009 GGI also received tentative approval for Atomoxetine Hydrochloride capsules, the generic version of Lilly's Strattera. Atomoxetine Hydrochloride capsules is ... Pharmaceutical Business Review Glenmark Generics gets tentative USFDA nod for 2 drugs - Dec 24, 2009 The company has also received tentative approval from USFDA for Atomoxetine Hydrochloride capsules, the generic version of Lilly`s Strattera. Myiris.com Boost je blok: studiebevorderende middelen - Dec 13, 2009 Minder bekende namen zijn Provigil (op basis van modafinil) en Strattera (op basis van atomoxetine). Het eigenlijke gebruik van deze middelen dient onder ... Veto ADHDå°?å©æœ‰é‹…銅ä¸?足的風險 - 14 Nov 2009 ...這些å©ç«¥ä¹‹ä¸ï¼Œ17人未曾用藥，18人æœ?用興奮劑ã€?9人æœ?用atomoxetine。 使用3天飲食日記與24å°?時回憶評估這些å°?å©çš„飲食。飲食評估巨é‡?ç‡Ÿé¤Šç´ /å¾®é‡?ç‡Ÿé¤Šç´ æ”?å?–與æ¯?æ—¥å»ºè° ... 臺灣新浪網 Aurobindo Pharma Likely to Market Perindopril Erbumine Tablets Shortly - Nov 12, 2009 Aurobindo Pharma had also received approval from US FDA in September 2009 for marketing the drug Atomoxetine Hydrochloride capsules in different strengths. MedIndia Cadila gets USFDA nod for Atomoxetine Hydrochloride capsules - Nov 3, 2009 Atomoxetine Hydrochloride Capsules are generic equivalent to Strattera of Eli Lily and company. The capsules are indicated for treatment of ... Myiris.com US nod for generic drug boosts Aurobindo Pharma - Nov 5, 2009 Aurobindo Pharma had on 19 September 2009 received tentative approval from US Food and Drug Adminstration (US FDA) for Atomoxetine Hydrochloride capsules in ... India Infoline.com Children With ADHD at Risk for Zinc and Copper Deficiency - Nov 3, 2009 Of these children, 17 were medication-naive, 18 were taking stimulant medications, and 9 were taking atomoxetine. The children's dietary intake was assessed ... Medscape REG-Lilly (Eli) & Co: Lilly Rpts Solid 3Q09; Rev Full-Year 09 EPS Guidance - Oct 21, 2009 Lilly) Strattera® (atomoxetine hydrochloride, Lilly) Zyprexa® (olanzapine, Lilly) Eli Lilly and Company Employment Information September 30, ... Reuters Brand Names/Synonyms: Atomoxetine is also known by the following brand names and/or synonymsAtomoxetine; Strattera; Tomoxetina [Spanish]; Tomoxetine; Tomoxetine [Inn]; Tomoxetinum [Latin] Drug Category: Atomoxetine is categorized under the following by the FDA: Antidepressants; Central Nervous System Agents; ATC:N06BA09 Dosage Forms: CAPSULE Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: N-methyl-3-(2-methylphenoxy)-3-phenyl-propan-1-amine |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |